407 related articles for article (PubMed ID: 26025767)
1. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE; Tryfonidis K; Slaets L; van Leeuwen-Stok AE; Skinner VP; Dif N; Pijnappel RM; Bijker N; Rutgers EJ; Wesseling J
Eur J Cancer; 2015 Aug; 51(12):1497-510. PubMed ID: 26025767
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
3. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
4. Addressing overtreatment of screen detected DCIS; the LORIS trial.
Francis A; Thomas J; Fallowfield L; Wallis M; Bartlett JM; Brookes C; Roberts T; Pirrie S; Gaunt C; Young J; Billingham L; Dodwell D; Hanby A; Pinder SE; Evans A; Reed M; Jenkins V; Matthews L; Wilcox M; Fairbrother P; Bowden S; Rea D
Eur J Cancer; 2015 Nov; 51(16):2296-303. PubMed ID: 26296293
[TBL] [Abstract][Full Text] [Related]
5. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
7. Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.
Alaeikhanehshir S; Voets MM; van Duijnhoven FH; Lips EH; Groen EJ; van Oirsouw MCJ; Hwang SE; Lo JY; Wesseling J; Mann RM; Teuwen J;
Cancer Imaging; 2024 Apr; 24(1):48. PubMed ID: 38576031
[TBL] [Abstract][Full Text] [Related]
8. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.
Prescrire Int; 2013 Dec; 22(144):298-303. PubMed ID: 24600734
[TBL] [Abstract][Full Text] [Related]
10. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study.
Sagara Y; Mallory MA; Wong S; Aydogan F; DeSantis S; Barry WT; Golshan M
JAMA Surg; 2015 Aug; 150(8):739-45. PubMed ID: 26039049
[TBL] [Abstract][Full Text] [Related]
11. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
[TBL] [Abstract][Full Text] [Related]
12. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
13. Current perspectives of treatment of ductal carcinoma in situ.
Estévez LG; Alvarez I; Seguí MÁ; Muñoz M; Margelí M; Miró C; Rubio C; Lluch A; Tusquets I
Cancer Treat Rev; 2010 Nov; 36(7):507-17. PubMed ID: 20462701
[TBL] [Abstract][Full Text] [Related]
14. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
15. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study.
Kuhl CK; Schrading S; Bieling HB; Wardelmann E; Leutner CC; Koenig R; Kuhn W; Schild HH
Lancet; 2007 Aug; 370(9586):485-92. PubMed ID: 17693177
[TBL] [Abstract][Full Text] [Related]
16. Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up.
Ringberg A; Andersson I; Aspegren K; Linell F
Eur J Surg Oncol; 1991 Oct; 17(5):466-76. PubMed ID: 1657650
[TBL] [Abstract][Full Text] [Related]
17. Non-surgical treatment for ductal carcinoma in situ of the breasts - a prospective study on patient's perspective.
Co M; Lee A; Kwong A
Cancer Treat Res Commun; 2021; 26():100241. PubMed ID: 33340904
[TBL] [Abstract][Full Text] [Related]
18. Should low-risk DCIS lose the cancer label? An evidence review.
Ma T; Semsarian CR; Barratt A; Parker L; Pathmanathan N; Nickel B; Bell KJL
Breast Cancer Res Treat; 2023 Jun; 199(3):415-433. PubMed ID: 37074481
[TBL] [Abstract][Full Text] [Related]
19. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
[TBL] [Abstract][Full Text] [Related]
20. Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed Low Risk DCIS Trial (LORIS).
Soumian S; Verghese ET; Booth M; Sharma N; Chaudhri S; Bradley S; Umranikar S; Millican-Slater RA; Hanby AM; Francis A
Eur J Surg Oncol; 2013 Dec; 39(12):1337-40. PubMed ID: 24209431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
